Yuan’s phase II study of anlotinib in pre-treated HER2 negative MBC showed that in patients had treatment failure after at least one prior chemotherapy regimen in the metastatic setting, the median PFS for anlotinib was 5.22 months (13), indicating a potential new treatment option for breast cancer. Here, ERBB2 is linked to breast carcinoma.